Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vs Intravenous Tranexamic Acid in FESS
NCT05686005Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Countries
- 1
- Sponsor
- Ain Shams University
- Modality
- Small Molecules
- Drugs
- tranexamic acid
- Conditions
- intraoperative bleeding
01
Overview
Phase 4, randomised, double-blind trial of tranexamic acid in intraoperative bleeding (3 arms), sponsored by Ain Shams University. Primary endpoint: Intraoperative field bleeding. Started Dec 2022; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Control
No intervention
Oral tranexamic
Oral tranexamic acid 2gm 2 hours before surgery
Intravenous tranexamic
Intravenous tranexamic acid 15mg/kg during induction
03
Who it enrols
Adults aged 18-40 scheduled for FESS under general anesthesia with ASA grade I or II, excluding those with history of thrombosis, cardiovascular diseases, chest problems, stroke, hepatic/renal failure, bleeding disorders, or taking opioids, sedatives, antiplatelets, or anticoagulants.
04
Endpoints
Primary
Intraoperative field bleeding
Secondary
Incidence of the common adverse effects
Post operative D-dimer
Beyond the preview
Go deeper on NCT05686005.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686005.